{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-23-000062","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.501209+00:00","generated_at":"2026-06-07T23:27:57.374337+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aerovate completes Phase 2b enrollment (202 patients) and enrolls first Phase 3 patient in AV-101 PAH trial","bullets":["Phase 2b portion of IMPAHCT trial enrolled 202 adult patients with PAH.","First patient enrolled in Phase 3 portion under adaptive trial design.","Topline Phase 2b data expected in June 2024.","Over 120 sites actively recruiting for Phase 3 globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-23-000062","json":"https://secwatch.observer/filing/0001798749-23-000062.json","markdown":"https://secwatch.observer/filing/0001798749-23-000062.md","text":"https://secwatch.observer/filing/0001798749-23-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000062/0001798749-23-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000062/tmb-20231120x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:27:57.374337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}